Details
Stereochemistry | ACHIRAL |
Molecular Formula | C14H30N2O4 |
Molecular Weight | 290.399 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 2 |
SHOW SMILES / InChI
SMILES
C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C
InChI
InChIKey=AXOIZCJOOAYSMI-UHFFFAOYSA-N
InChI=1S/C14H30N2O4/c1-15(2,3)9-11-19-13(17)7-8-14(18)20-12-10-16(4,5)6/h7-12H2,1-6H3/q+2
Succinylcholine also known as suxamethonium is a quaternary skeletal muscle relaxant usually used in the form of its halogen salt. It is is indicated under brand name anectine as an adjunct to general anesthesia, to facilitate tracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation. Succinylcholine activates the muscle-type nicotinic acetylcholine receptor followed by desensitization. Succinylcholine does not inhibit the presynaptic alpha3beta2 autoreceptor at clinically relevant concentrations, that provides a possible mechanistic explanation for the typical lack of tetanic fade in succinylcholine-induced neuromuscular blockade. Finally, was explored, that cardiovascular side effects (e.g., tachyarrhythmias) of succinylcholine were not mediated via direct activation of the autonomic ganglionic alpha3beta4 subtype because succinylcholine didn’t not activate the neuronal nicotinic acetylcholine receptor (nAChR) subtypes.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2362997 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16571968 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | ANECTINE Approved UseSuccinylcholine chloride is indicated as an adjunct to general anesthesia, to facilitate tracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation. Launch Date1952 |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
18.5 μg × min/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/14564614/ |
1 mg/kg bw single, intravenous dose: 1 mg/kg bw route of administration: Intravenous experiment type: SINGLE co-administered: |
SUCCINYLCHOLINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
58.6 μg × min/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/14564614/ |
2 mg/kg bw single, intravenous dose: 2 mg/kg bw route of administration: Intravenous experiment type: SINGLE co-administered: |
SUCCINYLCHOLINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
25.4 s EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/14564614/ |
1 mg/kg bw single, intravenous dose: 1 mg/kg bw route of administration: Intravenous experiment type: SINGLE co-administered: |
SUCCINYLCHOLINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
26.3 s EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/14564614/ |
2 mg/kg bw single, intravenous dose: 2 mg/kg bw route of administration: Intravenous experiment type: SINGLE co-administered: |
SUCCINYLCHOLINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
1.5 mg/kg single, intravenous Higher than recommended Dose: 1.5 mg/kg Route: intravenous Route: single Dose: 1.5 mg/kg Sources: Page: p.866 |
healthy, 31 n = 22 Health Status: healthy Condition: General anesthesia Age Group: 31 Sex: F Population Size: 22 Sources: Page: p.866 |
|
1.1 mg/kg single, intravenous (max) Recommended Dose: 1.1 mg/kg Route: intravenous Route: single Dose: 1.1 mg/kg Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: General anesthesia|Skeletal muscle relaxation Sources: Page: p.1 |
Disc. AE: Rhabdomyolysis, Ventricular arrhythmia... AEs leading to discontinuation/dose reduction: Rhabdomyolysis (acute, rare) Sources: Page: p.1Ventricular arrhythmia (rare) Cardiac arrest (grade 5, rare) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Rhabdomyolysis | acute, rare Disc. AE |
1.1 mg/kg single, intravenous (max) Recommended Dose: 1.1 mg/kg Route: intravenous Route: single Dose: 1.1 mg/kg Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: General anesthesia|Skeletal muscle relaxation Sources: Page: p.1 |
Cardiac arrest | grade 5, rare Disc. AE |
1.1 mg/kg single, intravenous (max) Recommended Dose: 1.1 mg/kg Route: intravenous Route: single Dose: 1.1 mg/kg Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: General anesthesia|Skeletal muscle relaxation Sources: Page: p.1 |
Ventricular arrhythmia | rare Disc. AE |
1.1 mg/kg single, intravenous (max) Recommended Dose: 1.1 mg/kg Route: intravenous Route: single Dose: 1.1 mg/kg Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: General anesthesia|Skeletal muscle relaxation Sources: Page: p.1 |
PubMed
Title | Date | PubMed |
---|---|---|
Succinylcholine-induced ventricular fibrillation in the paralyzed urology patient. | 1975 Jan |
|
Influence of tetrahydro-aminacrine on muscle pains after suxamethonium. | 1975 Jan 18 |
|
Hypersensitivity to suxamethonium in a Suffolk family. | 1976 Jul |
|
Cardiac arrest due to succinylcholine-induced hyperkalemia in a patient with wound botulism. | 2000 Feb |
|
Out-of-hospital succinylcholine-assisted endotracheal intubation by paramedics. | 2000 Jun |
|
[Anesthetic complications. The incidence of severe anesthetic complications in patients and families with progressive muscular dystrophy of the Duchenne and Becker types]. | 2000 Mar |
|
Choice of the muscle relaxant for rapid-sequence induction. | 2001 |
|
Choice of the hypnotic and the opioid for rapid-sequence induction. | 2001 |
|
Increased sensitivity to depolarization and nondepolarizing neuromuscular blocking agents in young rat hemidiaphragms. | 2001 Aug |
|
Safety and efficacy of rocuronium for controlled intubation with paralytics in the pediatric emergency department. | 2001 Aug |
|
Second dose thiopentone attenuates the haemodynamic response to laryngoscopy and intubation. | 2001 Feb |
|
Sore throat following tracheal intubation. | 2001 Feb |
|
Effectiveness of continuous positive airway pressure to enhance pre-oxygenation in morbidly obese women. | 2001 Jul |
|
Asystole during electroconvulsive therapy: a case report. | 2001 Jun |
|
Disagree with use of muscle relaxant before euthanasia. | 2001 Jun 15 |
|
Measurement of succinylcholine concentration in human plasma by electrospray tandem mass spectrometry. | 2001 Mar |
|
Maternal anaphylactic reaction to a general anaesthetic at emergency caesarean section for fetal bradycardia. | 2001 May |
|
Rapid sequence induction: a national survey of practice. | 2001 Nov |
|
Basotest and suxamethonium allergy. | 2001 Oct |
|
[Anesthesia for electroconvulsive therapy during pregnancy--a case report]. | 2001 Sep |
|
Autosomal dominant canine malignant hyperthermia is caused by a mutation in the gene encoding the skeletal muscle calcium release channel (RYR1). | 2001 Sep |
|
Succinylcholine in the intensive care unit. | 2002 Jan |
Patents
Sample Use Guides
Adults: For Short Surgical Procedures: the average dose required to produce neuromuscular blockade and to facilitate tracheal intubation is 0.6 mg/kg ANECTINE (Succinylcholine Chloride Injection) given intravenously. The optimum dose will vary among individuals and may be from 0.3 to 1.1 mg/kg for adults. Following administration of doses in this range, neuromuscular blockade develops in about 1 minute; maximum blockade may persist for about 2 minutes, after which recovery takes place within 4 to 6 minutes. However, very large doses may result in more prolonged blockade. A 5- to 10-mg test dose may be used to determine the sensitivity of the patient and the individual recovery time (see PRECAUTIONS). For Long Surgical Procedures The dose of succinylcholine administered by infusion depends upon the duration of the surgical procedure and the need for muscle relaxation. The average rate for an adult ranges between 2.5 and 4.3 mg per minute. Solutions containing from 1 to 2 mg per mL succinylcholine have commonly been used for continuous infusion. The more dilute solution (1 mg per mL) is probably preferable from the standpoint of ease of control of the rate of administration of the drug and, hence, of relaxation. This IV solution containing 1 mg per mL may be administered at a rate of 0.5 mg (0.5 mL) to 10 mg (10 mL) per minute to obtain the required amount of relaxation. Intermittent IV injections of succinylcholine may also be used to provide muscle relaxation for long procedures. An IV injection of 0.3 to 1.1 mg/kg may be given initially, followed, at appropriate intervals, by further injections of 0.04 to 0.07 mg/kg to maintain the degree of relaxation required.
Pediatrics: for emergency tracheal intubation or in instances where immediate securing of the airway is necessary, the IV dose of succinylcholine is 2 mg/kg for infants and small children; for older children and adolescents the dose is 1 mg/kg. Rarely, IV bolus administration of succinylcholine in infants and children may result in malignant ventricular arrhythmias and cardiac arrest secondary to acute rhabdomyolysis with hyperkalemia. In such situations, an underlying myopathy should be suspected. Intravenous bolus administration of succinylcholine in infants or children may result in profound bradycardia or, rarely, asystole. As in adults, the incidence of bradycardia in children is higher
Intramuscular Use: If necessary, succinylcholine may be given intramuscularly to infants, older children, or adults when a suitable vein is inaccessible. A dose of up to 3 to 4 mg/kg may be given, but not more than 150 mg total dose should be administered by this route. The onset of effect of succinylcholine given intramuscularly is usually observed in about 2 to 3 minutes.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/3790394
The rat diaphragm was used as an in vitro model for studies of contractures synergistically-induced by halothane and suxamethonium (succinylcholine). The effects of three agents reported to inhibit phospholipase A2 activity (quinacrine, spermine and indomethacin), tubocurarine and dantrolene were examined on these contractures. Contractures induced by 1% halothane (0.26 +/- 0.02 g) (mean +/- SEM) were increased (0.60 +/- 0.04 g) if suxamethonium 50 mmol litre-1 was also in the bathing medium. Suxamethonium-induced contractures (0.22 +/- 0.03 g) were also enhanced when halothane was present (0.51 +/- 0.03 g). Spermine, indomethacin and dantrolene antagonized both halothane- and suxamethonium-induced contractures. Quinacrine potentiated contractures induced by either halothane or suxamethonium. Contractures induced by suxamethonium were antagonized by tubocurarine; however, contractures induced by halothane were not antagonized by tubocurarine. These results suggest that free fatty acids may be involved in contractures induced synergistically by halothane and suxamethonium. Different mechanisms are involved in the induction of contractures by suxamethonium than by halothane.
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NDF-RT |
N0000175733
Created by
admin on Fri Dec 15 17:20:03 GMT 2023 , Edited by admin on Fri Dec 15 17:20:03 GMT 2023
|
||
|
WHO-ATC |
M03AB01
Created by
admin on Fri Dec 15 17:20:03 GMT 2023 , Edited by admin on Fri Dec 15 17:20:03 GMT 2023
|
||
|
NDF-RT |
N0000175719
Created by
admin on Fri Dec 15 17:20:03 GMT 2023 , Edited by admin on Fri Dec 15 17:20:03 GMT 2023
|
||
|
WHO-VATC |
QM03AB01
Created by
admin on Fri Dec 15 17:20:03 GMT 2023 , Edited by admin on Fri Dec 15 17:20:03 GMT 2023
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
20
Created by
admin on Fri Dec 15 17:20:03 GMT 2023 , Edited by admin on Fri Dec 15 17:20:03 GMT 2023
|
||
|
NCI_THESAURUS |
C29696
Created by
admin on Fri Dec 15 17:20:03 GMT 2023 , Edited by admin on Fri Dec 15 17:20:03 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
Succinylcholine
Created by
admin on Fri Dec 15 17:20:03 GMT 2023 , Edited by admin on Fri Dec 15 17:20:03 GMT 2023
|
PRIMARY | |||
|
2489
Created by
admin on Fri Dec 15 17:20:03 GMT 2023 , Edited by admin on Fri Dec 15 17:20:03 GMT 2023
|
PRIMARY | |||
|
C61955
Created by
admin on Fri Dec 15 17:20:03 GMT 2023 , Edited by admin on Fri Dec 15 17:20:03 GMT 2023
|
PRIMARY | |||
|
10154
Created by
admin on Fri Dec 15 17:20:03 GMT 2023 , Edited by admin on Fri Dec 15 17:20:03 GMT 2023
|
PRIMARY | RxNorm | ||
|
DB00202
Created by
admin on Fri Dec 15 17:20:03 GMT 2023 , Edited by admin on Fri Dec 15 17:20:03 GMT 2023
|
PRIMARY | |||
|
SUB04653MIG
Created by
admin on Fri Dec 15 17:20:03 GMT 2023 , Edited by admin on Fri Dec 15 17:20:03 GMT 2023
|
PRIMARY | |||
|
D013390
Created by
admin on Fri Dec 15 17:20:03 GMT 2023 , Edited by admin on Fri Dec 15 17:20:03 GMT 2023
|
PRIMARY | |||
|
45652
Created by
admin on Fri Dec 15 17:20:03 GMT 2023 , Edited by admin on Fri Dec 15 17:20:03 GMT 2023
|
PRIMARY | |||
|
DTXSID7048455
Created by
admin on Fri Dec 15 17:20:03 GMT 2023 , Edited by admin on Fri Dec 15 17:20:03 GMT 2023
|
PRIMARY | |||
|
306-40-1
Created by
admin on Fri Dec 15 17:20:03 GMT 2023 , Edited by admin on Fri Dec 15 17:20:03 GMT 2023
|
PRIMARY | |||
|
Succinylcholine
Created by
admin on Fri Dec 15 17:20:03 GMT 2023 , Edited by admin on Fri Dec 15 17:20:03 GMT 2023
|
PRIMARY | |||
|
J2R869A8YF
Created by
admin on Fri Dec 15 17:20:03 GMT 2023 , Edited by admin on Fri Dec 15 17:20:03 GMT 2023
|
PRIMARY | |||
|
4004
Created by
admin on Fri Dec 15 17:20:03 GMT 2023 , Edited by admin on Fri Dec 15 17:20:03 GMT 2023
|
PRIMARY | |||
|
100000086059
Created by
admin on Fri Dec 15 17:20:03 GMT 2023 , Edited by admin on Fri Dec 15 17:20:03 GMT 2023
|
PRIMARY | |||
|
3254
Created by
admin on Fri Dec 15 17:20:03 GMT 2023 , Edited by admin on Fri Dec 15 17:20:03 GMT 2023
|
PRIMARY | |||
|
J2R869A8YF
Created by
admin on Fri Dec 15 17:20:03 GMT 2023 , Edited by admin on Fri Dec 15 17:20:03 GMT 2023
|
PRIMARY | |||
|
5314
Created by
admin on Fri Dec 15 17:20:03 GMT 2023 , Edited by admin on Fri Dec 15 17:20:03 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)